ALOX5 contributes to glioma progression by promoting 5-HETE-mediated immunosuppressive M2 polarization and PD-L1 expression of glioma-associated microglia/macrophages
Our findings reveal a pivotal role of the ALOX5/5-HETE axis in regulating GAMs and highlight the ALOX5-targeted nanobody as a potential therapeutic agent, which could potentiate immune checkpoint therapy for glioma.
Authors
- Chenci Wang (ORCID: https://orcid.org/0000-0002-7114-1295)
- Tingzheng Pan
- Zhengwei Wang (ORCID: https://orcid.org/0000-0002-8026-2208)
- Jiani Lin
- Jie Mao (ORCID: https://orcid.org/0000-0001-6082-9732)
- Jiayi Zhou (ORCID: https://orcid.org/0000-0002-3274-1802)
- Zhuohao Liu (ORCID: https://orcid.org/0000-0003-2487-3140)
- Jiangang Liu (ORCID: https://orcid.org/0000-0002-2800-077X)
- Dinglan Wu (ORCID: https://orcid.org/0000-0002-5057-9626)
- Hongchao Xu
- Tao Chen (ORCID: https://orcid.org/0000-0002-3634-0854)
- Jianwei Wang (ORCID: https://orcid.org/0000-0002-1116-4559)
- Xiaosheng He (ORCID: https://orcid.org/0000-0002-6581-4043)
Institutions
- Sun Yat-sen University (CN)
- Guilin Medical University (CN)
- Third Affiliated Hospital of Southern Medical University (CN)
- Longgang Central Hospital (CN)
- Fuyang City People's Hospital (CN)
- The Seventh Affiliated Hospital of Sun Yat-sen University (CN)
- Southern Medical University Shenzhen Hospital (CN)
- Fuyang Second People's Hospital (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1136/jitc-2024-009492
- Citations
- 15
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 3.61
Funders
- National Natural Science Foundation of China